insightscare Interview: BioMark Diagnostics Inc: Innovating Cancer Detection
BioMark Diagnostics Inc: Innovating Cancer Detection From the interview originally published by insightscare https://insightscare.com/biomark-diagnostics-inc-innovating-cancer-detection/ Rashid A Bux | CEO and Founder | BioMark Diagnostics Inc A dynamic field like diagnostics requires efficient technologies for detecting diseases and critical illnesses. One organization that stands out with its innovative solutions in pursuit of this universal mission is BioMark […]
BIOMARK ANNOUNCES RECENT NEW PATENT GRANTED IN CANADA TO SUPPORT ITS LIQUID BIOPSY BASED LEGACY ASSAY
BIOMARK ANNOUNCES RECENT NEW PATENT GRANTED IN CANADA TO SUPPORT ITS LIQUID BIOPSY BASED LEGACY ASSAY Vancouver, British Columbia – (December 4th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) a clinical and diagnostic laboratory developing a liquid biopsy molecular diagnostic tests with a focus on hard to […]
Form 7 Monthly Progress Report November 2023
Form 7 Monthly Progress Report November 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 December 4, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BIOMARK PROVIDES SECOND QUARTER OPERATIONAL UPDATE AND ANNOUNCES EXTENSION TO WARRANT EXERCISE TERM
BIOMARK PROVIDES SECOND QUARTER OPERATIONAL UPDATE AND ANNOUNCES EXTENSION TO WARRANT EXERCISE TERM Vancouver, British Columbia – (November 28th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers today reports strong operational results […]
BIOMARK STRENGTHENS AND EXPANDS ITS STRATEGIC ADVISORY TEAM IN PURSUIT OF COMMERCIALIZATION INITIATIVES
BIOMARK STRENGTHENS AND EXPANDS ITS STRATEGIC ADVISORY TEAM IN PURSUIT OF COMMERCIALIZATION INITIATIVES Dr. W. Randolph Ford, Ph.D., will be joining BioMark’s Advisory team to support Artificial Intelligence and Machine Learning capabilities. Vancouver, British Columbia – (November 14th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy […]
BIOMARK ANNOUNCES FINANCIAL CONTRIBUTION FROM THE CITY OF QUEBEC TO SUPPORT COMMERCIALIZATION INITIATIVES OF ITS PROPRIETARY LUNG CANCER DETECTION TEST
BIOMARK ANNOUNCES FINANCIAL CONTRIBUTION FROM THE CITY OF QUEBEC TO SUPPORT COMMERCIALIZATION INITIATIVES OF ITS PROPRIETARY LUNG CANCER DETECTION TEST Vancouver, British Columbia and Québec City, Québec – (November 7, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) a leading liquid biopsy company focusing on metabolomics for the early diagnosis of […]
BIOMARK TO UNVEIL RESULTS OF ITS EARLY BREAST CANCER STUDY AT THE UPCOMING SAN ANTONIO BREAST CANCER SYMPOSIUM
BIOMARK TO UNVEIL RESULTS OF ITS EARLY BREAST CANCER STUDY AT THE UPCOMING SAN ANTONIO BREAST CANCER SYMPOSIUM Analyses from a retrospective study of early breast cancer metabolomics panel further demonstrate the diagnostic power of BioMark’s liquid biopsy platform beyond early lung cancer detection. Vancouver, British Columbia – (October 24th, 2023) – BioMark Diagnostics Inc. […]
Form 7 Monthly Progress Report October 2023
Form 7 Monthly Progress Report October 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 November 3, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Form 7 Monthly Progress Report September 2023
Form 7 Monthly Progress Report September 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 October 1, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Une Technologie d’ici Pour Mieux Diagnostiquer le Cancer du Poumon – Local Technology for Improved Lung Cancer Diagnosis
Une Technologie d’ici Pour Mieux Diagnostiquer le Cancer du Poumon – Local Technology for Improved Lung Cancer Diagnosis This article recently appeared in the French-Canadian news publication “Le Soleil”. The origjnal article can be found here: https://www.lesoleil.com/affaires/2023/08/30/une-technologie-dici-pour-mieux-diagnostiquer-le-cancer-du-poumon-WMYOCY325FC65HU4ISBUQWJT5U/ The following is an AI translation of the text of the article to English: “Local Technology for Improved […]
